Argenx's Forte Bio Deal Validates CEO Change -- Market Talk
Dow Jones2026/07/28 08:230823 GMT - Argenx's $2.2 billion deal to acquire Forte Biosciences should help the European pharmaceutical company diversify its portfolio and validates a CEO transition that took place earlier this year, Bernstein analysts say in a note. Argenx currently has one successful growth driver, its Vyvgart drug for rare neuromuscular disease myasthenia gravis, but its U.S. patent is due to expire in 2036, the analysts say. The next five years are key for broadening and deepening its pipeline, and the Forte deal helps it lower portfolio-concentration risk, they add. "Moreover, a key reason why [Argenx] underwent its CEO transition in [January] was to try to accelerate complementing its organic pipeline with interesting external assets," Bernstein says. Argenx's shares fall 0.7%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
July 28, 2026 04:23 ET (08:23 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
PNC Bank Launches USDC Payment Acceptance for Corporate Clients
British Pound tumbles below 1.33 post hot US CPI, Fed hawkish rhetoric
Morgan Stanley warns: old storage prices are peaking, supply and demand may turn relaxed by 2028
Morgan Stanley pointed out that after the U.S. midterm elections, it is expected that about 20% of the new data center capacity in the United States originally planned for 2028 will be postponed to 2029. This may cause a "gap" in the supply chain in 2028, resulting in the risk of excess inventory of legacy storage. Legacy storage is less bound by long-term fixed price contracts, so a narrowing supply-demand gap could lead to significant price fluctuations. The above analysis refers only to legacy storage, including DDR3/4, SLC/MLC NAND, and NOR flash.
Crypto prices
More
